Avid Bioservices ( (CDMO) ) just unveiled an announcement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Avid Bioservices, a biologics contract development and manufacturing organization, is set to be acquired by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion all-cash transaction. Shareholders will receive $12.50 per share, representing a premium to recent trading prices. The merger is expected to close in early 2025, subject to customary conditions and approvals. This acquisition aims to leverage the expertise and capital of GHO and Ampersand to propel Avid’s growth and market reach.
Learn more about CDMO stock on TipRanks’ Stock Analysis page.
